Pain intensity at presentation is a survival predictor in head and neck cancer
the ONA take:
Pain is the most significant side effect of cancer and its treatments. Researchers at M.D. Anderson Cancer Center assessed the extent to which pain severity influenced prognosis in 2,340 patients with newly diagnosed head and neck cancer.
They found pain severity to be an independent predictor of survival among patients with oral cancer. Squamous cell cancer is the most prevalent head and neck cancer, which includes cancers of the oral cavity, tongue, pharynx, and larynx. Pain occurs in these cancers as a first sign of disease, due to the direct involvement of tissue and bone, as well as a result of treatments such as surgery, chemotherapy, and radiation.
In this assessment, patients were asked to rate their pain on a scale of 0 (no pain) to 10 (“pain as bad as you can imagine”) at first presentation. Severe pain was reported by 19% of patients, and was most prevalent in patients with oral cancer. Survival time was calculated from diagnosis to death or last follow-up. Overall, 5-year survival was higher among patients with oral cancer who did not report severe pain. Similar results were seen among patients with pharyngeal cancer, as well.
The researchers conclude that severe pain at presentation is a significant factor in patients with head and neck cancer, and pain should be assessed and promptly treated.
Researchers assessed the extent to which pain severity influenced prognosis.
Pre-treatment pain intensity is an independent survival predictor for patients with head and neck cancer, according to new research published in The Journal of Pain, the peer-reviewed publication of the American Pain Society. Researchers at M.D. Anderson Cancer Center assessed the extent to which pain severity influences survival in 2,340 newly diagnosed patients with head and neck cancer.
At first presentation, patients rated their pain using a scale in which 0 meant no pain and 10 indicated "pain as bad as you can imagine." Survival time was calculated from diagnosis to death or last follow-up.
- Novel Colonoscopy Prep Is Poised to Improve Screening Rates for Colon Cancer
- PPIs Negatively Impact Outcomes of Patients Treated With Capecitabine
- How Physical Changes From Breast Cancer Affect Self-Image: Considerations for Clinicians
- Short-Term Intervention May Have Long-term Diet Effect in Hispanic Breast Cancer Survivors
- Panobinostat Modestly Improves OS in Relapsed Multiple Myeloma
- Overall Benefits of Vaporized Nicotine Products Outweigh Harms, Says International Panel of Experts
- Sugar and Cancer: Mitigating the Affects of Diet on Cancer
- Nurse Residency Programs Can Impact Oncology Nursing Practice, Outcomes
- Implementing a Distress Screening Process for Cancer Patients
- Initiating Palliative Care in the Emergency Department
- Childhood Cancer Linked to Poor Diet Quality in Adult Survivors
- Atypical Teratoid/rhabdoid Tumors: Challenges and Search for Solutions
- New Research Identifies Potential Bladder Cancer Chemotherapy Side Effect
- Pseudohyperkalemia: False Potassium Levels Occur in a Patient With Lymphoma
- Atezolizumab Granted FDA Approval for Specific Cases of NSCLC
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|